Results 11 to 20 of about 33,791,512 (292)
Glucagon-like peptide-1 analogues: An overview
Indian Journal of Endocrinology and Metabolism, 2013 Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function.
Vishal Gupta
doaj +3 more sources
The binding and activation of the glucagon-like peptide-1 receptor by exendin-4 [PDF]
, 2010 Background and purpose Exendin-4 (EX4) has the same physiological properties as glucagon-like peptide-1 (7-36)amide (GLP-1). EX4 has 50% identity with GLP-1, with an extra nine amino acids at its C-terminus.
Nasr, Elsayed Mohammed Nasr
core +6 more sources
Glucagon-like peptide 1 and appetite [PDF]
Trends in Endocrinology & Metabolism, 2013 Glucagon-like peptide 1 (GLP-1) and GLP-1 analogs have received much recent attention due to the success of GLP-1 mimetics in treating type II diabetes mellitus (T2DM), but these compounds may also have the potential to treat obesity. The satiety effect of GLP-1 may involve both within-meal enteroenteric reflexes, and across-meal central signaling ...
Megan J, Dailey, Timothy H, Moran
openaire +2 more sources
Glucagon-like peptide-1 receptor imaging for localization of insulinomas [PDF]
, 2009 The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be ...
Clerici, Thomas +21 more
core +3 more sources
Recent Progress in Hormone Research, 2001 There is a progressive impairment in beta-cell function with age. As a result, 19 percent of the U.S. population over the age of 65 is diagnosed with type 2 diabetes mellitus (DM). Glucagon-like peptide-1 (GLP-1) is a potent insulin secretagogue that has multiple synergetic effects on the glucose-dependent insulin secretion pathways of the beta-cell ...
M E, Doyle, J M, Egan
openaire +2 more sources
Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro [PDF]
, 2003 The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine ...
Dufès, Christine +4 more
core +4 more sources
Glucagon-Like Peptide-1 and Diabetes [PDF]
Experimental Diabetes Research, 2011 This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire +2 more sources
Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion [PDF]
, 2010 Context: Glucagon-like peptide-1 (GLP-1) is produced by specialized cells in the gut and secreted in response to carbohydrates and lipids. The mechanisms regulating fat-stimulated GLP-1 release have, however, not been clarified in detail.
Schirra, Joerg +5 more
core +1 more source
Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]
, 2010 Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Deepson S Shyangdan +18 more
core +2 more sources
Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition
World Nutrition, 2019 There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj +1 more source